Who was studied, and how
Six numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 12 other studies
154people with obesity, in this paper
The trial randomly assignedassigned by chance
once-weekly subcutaneous semaglutide
placebo
Probably lowered long-term blood sugar−0.46
Probably lowered body weight−9.21
Probably raised high-density cholesterol+10.8
randomisedthe abstract, start to end
Semaglutide reduced HbA1c by 0.46% of total hemoglobin (95% CI, -0.56% to -0.36%) and body weight by 9.21 kg (95% CI, -11.68 to -6.75).
… in high-density cholesterol by 10.81 mg/dL (95% CI, 2.70-18.53; P = .007) and triglycerides by -29.20 mg/dL (95% CI, -55.75 to 2.65; …
… semaglutide improved physical QoL by 3.75 points on the SF-36v2 (95% CI, 1.52-5.98; P = .001) …
← favours treatmentfavours comparator →
could be chanceChange in HbA1conce-weekly subcutaneous semaglutide vs placebo
−0.46−0.56 to −0.36
Change in body weightonce-weekly subcutaneous semaglutide vs placebo
−9.21−11.7 to −6.75
High-density cholesterolonce-weekly subcutaneous semaglutide vs placebo
10.812.70–18.5
Triglyceridesonce-weekly subcutaneous semaglutide vs placebo
−29.20−55.8 to 2.65
Physical QoLonce-weekly subcutaneous semaglutide vs placebo
3.751.52–5.98
Quality of life & behaviour
21.52–5.98
GLP-1 receptor agonistsGlycemic controlBody weight & compositionLipidsQuality of life & behaviour
GLP-1 receptor agonists × quality of life & behaviourhelps?mixed
unlikelylikely
0.440.37 without it
GLP-1 receptor agonists × lipidshelps?one trial
unlikelylikely
0.500.50 without it
GLP-1 receptor agonists × body weight & compositionhelps?replicated
unlikelylikely
0.900.90 without it
← favours comparatorfavours treatment →
1 / 6